FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

October 10, 2017: By Joan McKenna

SparkSpark Therapeutics’ gene therapy candidate for inherited retinal disease will be reviewed Oct. 12 by the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee.

The panel will consider whether to recommend voretigene neparvovec, branded Luxturna, for the treatment of patients with vision loss due to retinal dystrophy caused by flaws in the RPE65 gene.

Spark says the gene mutation breaks the visual cycle of light activating photoreceptors, resulting in progressive vision loss and often near blindness.

The FDA has granted orphan drug, breakthrough therapy, and rare pediatric disease designations for voretigene neparvovec, a one-time treatment.

Spark estimates that disease affects an estimated 1 thousand to 3 thousand patients in the US.

Philadelphia-based Spark, founded in March 2013, now has a workforce of 300 industry professionals and has secured $1 billion in financing. It has a pipeline of eight investigational gene therapies. Luxturna is its lead candidate.

The panel meeting will run 8:30 to 5 p.m. Oct. 12 at the FDA’s White Oak Campus in Silver Spring, Maryland.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022